glp-1 suicide US FDA removes suicidal thoughts warning from weight-loss drugs MHRA finds evidence does not
Description
Diabetes Research and Clinical Practice , 199, 110634
No participants discontinued the trial solely because of fatigue
Adjust expectations accordingly
The focus of this lawsuit lies in the manufacturers negligence in providing adequate warning practices, failure to deliver sufficient cautionary information, and breach of warranty
